Table 3.
Insertion and potential direct-acting antivirals resistance-associated substitutions of DE/−17–0414
| Genomic regions | Amino acid position | Reference amino acid | DE/−17–0414 | Susceptibility to DAA according to Geno2Pheno[HCV] (Kalaghatgi et al., 2016) |
|---|---|---|---|---|
| E2 | 1a-1c | – | QSR | NAa |
| NS3 | 36 | V | L | Substitution on scored position to Asunaprevir, Grazoprevir, Ledipasvir, Paritaprevir; Reduced susceptibility to Simeprevir, Telaprevir, Voxilaprevir; Resistant to Boceprevir |
| NS3 | 170 | I | V | Substitution on scored position to Voxilaprevir |
| NS5A | 28 | L | M | Substitution on scored position to Ombitasvir |
| NS5A | 31 | L | M | Substitution on scored position to Velpatasvir |
| NS5A | 93 | Y | H | Substitution on scored position to Pibrentasvir; Resistant to Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Velpatasvir |
aNA for not available